Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Resultados financieros en millones de dólares estadounidenses. El ejercicio fiscal es febrero - enero.
Breakdown
TTM
06/30/2025
06/30/2024
06/30/2023
06/30/2022
06/30/2021
Ingresos
1
0
0
0
0
0
Crecimiento de los Ingresos (YoY)
--
--
--
--
--
--
Costo de los ingresos
--
--
--
--
--
--
Utilidad bruta
--
--
--
--
--
--
Venta, General y Administración
7
5
4
5
5
7
Investigación y Desarrollo
16
14
18
13
14
12
Gastos de Operación
17
14
19
14
15
15
Otras Ingresos (Gastos) No Operativos
2
2
0
0
0
0
Ingreso antes de impuestos
-14
-12
-19
-13
-12
-15
Gasto por Impuesto a la Renta
0
0
0
0
0
0
Ingreso Neto
-14
-12
-19
-13
-12
-15
Crecimiento de la Utilidad Neta
-26%
-37%
46%
8%
-20%
15%
Acciones en Circulación (Diluidas)
10,684.27
6,396.92
3,648.87
2,427.84
2,405.99
1,696.87
Cambio de Acciones (YoY)
109%
75%
50%
1%
42%
90%
EPS (Diluido)
0
0
0
0
0
0
Crecimiento de EPS
-60%
-63%
-9%
8%
-41%
-40%
Flujo de efectivo libre
-22
-11
-12
-20
-12
-17
Flujo de efectivo libre por acción
--
--
--
--
--
--
Margen bruto
--
--
--
--
--
--
Margen de operación
-1,600%
0%
0%
0%
0%
0%
Margen de beneficio
-1,400%
0%
0%
0%
0%
0%
Margen de flujo de caja libre
-2,200%
0%
0%
0%
0%
0%
EBITDA
-16
-14
-19
-14
-15
-15
Margen de EBITDA
-1,600%
0%
0%
0%
0%
0%
D&A para EBITDA
0
0
0
0
0
0
EBIT
-16
-14
-19
-14
-15
-15
Margen de EBIT
-1,600%
0%
0%
0%
0%
0%
Tasa de Impuesto Efectiva
0%
0%
0%
0%
0%
0%
Follow-Up Questions
Alterity Therapeutics Limited'in temel mali tabloları nelerdir?
Son mali tabloya (Form-10K) göre, Alterity Therapeutics Limited'in toplam varlıkları $0 olup, net pérdida $-12'dir.
ATHE'ün temel finansal oranları nelerdir?
Alterity Therapeutics Limited'in cari oranı 0, net kâr marjı 0, hisse başına satış $0'dir.
Alterity Therapeutics Limited'in geliri segment veya coğrafya bazında nasıl dağılıyor?
El segmento de ingresos más grande es Alterity Therapeutics Limited, con unos ingresos de Professional Services en el último informe de ganancias. En cuanto a la geografía, United States es el mercado principal para Alterity Therapeutics Limited, con unos ingresos de 59,793,006.
Alterity Therapeutics Limited kârlı mı?
no, son mali tablolara göre Alterity Therapeutics Limited'in net pérdida $-12'dir.
Alterity Therapeutics Limited'in herhangi bir yükümlülüğü var mı?
no, Alterity Therapeutics Limited'in yükümlülüğü 0'dir.
Alterity Therapeutics Limited'in tedavüldeki hisse sayısı kaçtır?
Alterity Therapeutics Limited'in toplam tedavüldeki hisse sayısı 0'dir.